Of these patients, 45 (52%) received 4 mg dexamethasone premedication prior to each fraction of SBRT and 41 (48%) were treated without dexamethasone premedication
Overall acute lung toxicity was low in both groups
837577 Corpus ID: 57520153; Influence of Dexamethasone Premedication on Acute Lung Toxicity in Lung SBRT @article{Alite2018InfluenceOD, title={Influence of Dexamethasone Premedication on Acute Lung Toxicity in Lung SBRT}, author={Fiori Alite and Parvez M
SBRT is commonly applied for thoracic malignancies, and is the standard of care for patients with early-stage, inoperable non-small cell lung cancer ( 1, 2 )
The combination therapy of nintedanib and dexamethasone resulted in a temporary improvement in Images
The applications of thoracic SBRT has expanded over time and it is now increasingly used for the ablative treatment of metastatic lesions, particularly in the settings of oligometastatic and oligoprogressive Clinical Practice Guidelines
Two phase III trials in adult patients with non-small-cell lung cancers evaluating a platinum-based doublet with or without the programmed death 1 (PD-1) inhibitor pembrolizumab recommended that all patients receive dexamethasone as a component of the prophylactic antiemetic regimen
Herein, we report a case of RILI with progressive pulmonary fibrosis after stereotactic body radiation therapy in a 70-year-old man with lung cancer
In patients who are not surgical candidates or are unwilling to undergo surgery, radiotherapy is the principal treatment option
Stereotactic body radiotherapy (SBRT) is a type of radiation therapy that uses many beams of energy
For example, steroids such as Decadron (dexamethasone) control brain swelling
Although systemic therapy is standard management for patients with metastatic disease, several recent reports have indicated that an addition of local therapies including stereotactic body radiation therapy (SBRT) for patients with oligometastatic disease (OMD) could improve survival
Surgical resection is an important treatment for early‐stage nonsmall‐cell lung cancer (NSCLC) patients
The aim of SBRT is to employ the highest possible dose of radiation to kill cancer while minimizing damage to surrounding tissues and organs
Stereotactic body radiation therapy, or SBRT, uses advanced imaging techniques to deliver a targeted radiation dose to a tumor, often for early stage lung cancer patients
Of these patients, 45 (52%) received 4 mg dexamethasone premedication prior to each fraction of SBRT and 41 (48%) were treated without dexamethasone premedication
Given the encouraging data in terms of local control and toxicity profile, SBRT has currently become a treatment option for both early stage lung cancer and lung oligometastatic disease in patients who are medically inoperable or refuse surgical resection
We analyzed 219 patients and 316 lung metastases treated between 2004 and 2019
SBRT is also used to treat The lung SBRT literature notes very low incidences of chest wall pain with BED <100 Gy in a single dose
in a single dose, or equivalent) 15-60 minutes before each SBRT treatment for the intended purpose of modulating immediate pulmonary inflammatory effects
It is also used to treat acute lymphoblastic leukemia Squamous cell carcinoma (SCC) of the lung, also known as squamous cell lung cancer, is a type of non-small cell lung cancer (NSCLC)
1-6 SBRT differs from conventional fractionated radiation therapy treatment in the delivery of large doses in a small number of fractions (typically SBRT total dose is delivered in 3 to 5 treatment Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial
The management of electron density discrepancies may vary greatly
The aim of this single-center retrospective analysis was to evaluate the safety and efficacy of protracted SBRT with 60 Gy in 12 fractions (with a biological Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial
To our knowledge, this represents the first report analyzing the influence of
uate the impact of severe TRL in the setting of lung cancer treated with SBRTon overall survival and evaluate potential strategies to minimize TRL
Loyola University Medical Center
Of these patients, 45 (52%) received 4 mg dexamethasone premedication prior to each fraction of SBRT and 41 (48%) were treated without dexamethasone
International Journal of Radiation
Herein, we report a case of RILI with progressive pulmonary fibrosis after stereotactic body radiation therapy in a 70-year-old man with lung cancer
Alite and others published Influence of Dexamethasone Premedication on Acute Lung Toxicity in Lung SBRT | Find, read and cite all the research you need on ResearchGate A total of 86 patients treated with thoracic SBRT with 54–60 Gy in 3–8 fractions met inclusion criteria, with the majority (70%) receiving 5 fractions
Pneumonitis is caused by direct cytotoxic effect, oxidative stress, and immune-mediated injury
A total of 86 patients treated with thoracic SBRT with 54–60 Gy in 3–8 fractions met inclusion criteria, with the majority (70%) receiving 5 fractions
Fatigue or muscle weakness
Search life-sciences literature (Over 40 million articles, preprints and more) 2
Two phase III trials in adult patients with non–small-cell lung cancers evaluating a platinum-based doublet with or without the programmed death 1 (PD-1) inhibitor pembrolizumab recommended that all patients receive dexamethasone as a
2022
Isolated local recurrence occurred in 44 of 803 patients, with 25 patients receiving SBRT reirradiation
Data reported are the best possible data obtainable from the present literature
1 , 2 For these NSCLC patients, stereotactic body radiation
Among NSCLC, adenocarcinoma is the most common, followed by squamous cell carcinoma of the lung, especially in women